文献速递其他结缔组织病

系统性硬化症相关雷诺现象评估问卷(ASRAP)的结构效度与信度

Construct validity and reliability of the Assessment of Systemic Sclerosis-Associated Raynaud's Phenomenon (ASRAP) questionnaire.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

这项国际多中心验证研究纳入420例系统性硬化症(SSc)患者,评估27条目的ASRAP问卷及10条目简版(ASRAP-SF)的结构效度与信度。ASRAP与雷诺现象视觉模拟量表(VAS)及Scleroderma健康评估问卷RP VAS相关性良好(rho 0.648–0.727,P<0.001),在症状稳定患者中1周重测信度优异(组内相关系数0.891和0.848,P<0.001);患者可接受症状状态阈值为45.34和45.77,初步最小重要临床差异阈值为4.17(95%CI 0.53, 7.81,P=0.029)。结论认为ASRAP与ASRAP-SF是评估SSc-RP严重程度及影响的有效、可靠的新患者报告结局工具。

要点

  • ASRAP及ASRAP-SF与RP VAS和Scleroderma HAQ RP VAS相关性良好(rho 0.648–0.727,P<0.001)。
  • 在SSc-RP症状稳定的患者中,1周重测组内相关系数分别为0.891和0.848(P<0.001)。
  • ASRAP与ASRAP-SF的患者可接受症状状态阈值分别为45.34和45.77。

核心结论

  • ASRAP与ASRAP-SF问卷是评估SSc-RP严重程度及影响的有效、可靠的新型患者报告结局工具。

研究设计与样本

  • 国际多中心验证研究,评估27条目ASRAP问卷及10条目简版ASRAP-SF,共纳入420例SSc受试者。
  • 评估ASRAP问卷与人口学、临床表型及评估SSc-RP严重程度、失能及疼痛的既有工具之间的关系,并在1周时评估重测信度。
  • 采用基于锚定的健康状态陈述评估ASRAP阈值的含义。

主要发现

  • ASRAP及ASRAP-SF与RP视觉模拟量表(VAS)及Scleroderma健康评估问卷RP VAS相关性良好(rho范围0.648–0.727,P<0.001)。
  • 与基于日记的SSc-RP发作频率及持续时间评估相关性较低(rho范围0.258–0.504,P<0.001)。
  • ASRAP问卷与评估失能、手功能、疼痛及总体健康评估的工具相关性良好(rho范围0.427–0.575,P<0.001)。
  • 吸烟者、有活动性指端溃疡(DU)者、有DU既往史者及有钙质沉着者的ASRAP评分显著更高(所有比较P<0.05)。
  • 在SSc-RP症状稳定的患者中,1周重测信度优异(组内相关系数0.891和0.848,P<0.001)。

关键数值与推荐

  • ASRAP的患者可接受症状状态阈值为45.34,ASRAP-SF为45.77。
  • 初步估计的最小重要临床差异阈值为4.17(95%CI 0.53, 7.81,P=0.029)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Assessment of construct validity and reliability of a novel patient-reported outcome (PRO) instrument for assessing the severity and impact of RP in SSc. METHODS: An international multicentre study validation study of the 27-item Assessment of Systemic Sclerosis-Associated Raynaud's Phenomenon (ASRAP) and 10-item short-form (ASRAP-SF) questionnaires. The relationship between ASRAP questionnaires and demographics, clinical phenotype and legacy instruments for assessing SSc-RP severity, disability and pain was assessed. Repeatability was evaluated at 1 week. Anchor-based statements of health status facilitated assessment of ASRAP thresholds of meaning. RESULTS: A total of 420 SSc subjects were enrolled. There was good correlation between ASRAP (and ASRAP-SF) with RP visual analogue scale (VAS) and Scleroderma Health Assessment Questionnaire RP VAS (rho range 0.648-0.727, P < 0.001). Correlation with diary-based assessment of SSc-RP attack frequency and duration was lower (rho range 0.258-0.504, P < 0.001). ASRAP questionnaires had good correlation with instruments for assessing disability, hand function, pain and global health assessment (rho range 0.427-0.575, P < 0.001). Significantly higher ASRAP scores were identified in smokers, patients with active digital ulceration (DU), previous history of DU and calcinosis (P < 0.05 for all comparisons). There was excellent repeatability at 1 week among patients with stable SSc-RP symptoms (intra-class coefficients of 0.891 and 0.848, P < 0.001). Patient-acceptable symptom state thresholds for ASRAP and ASRAP-SF were 45.34 and 45.77, respectively. A preliminary Minimally Important Clinical Difference threshold of 4.17 (95% CI 0.53, 7.81, P = 0.029) was estimated. CONCLUSION: ASRAP and ASRAP-SF questionnaires are valid and reliable novel PRO instruments for assessing the severity and impact of SSc-RP.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pauling JD, Yu L, Frech TM, et al. Construct validity and reliability of the Assessment of Systemic Sclerosis-Associated Raynaud's Phenomenon (ASRAP) questionnaire. Rheumatology (Oxford). 2024. PMID: 37481713. doi:10.1093/rheumatology/kead371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。